Who is sponsoring NCT05147324?

NCT05147324 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT05147324?

Interventions in NCT05147324: "MyPlan" - Individualized Planned Eating Pattern.

What condition does NCT05147324 study?

NCT05147324 studies Type 1 Diabetes.

Is NCT05147324 still recruiting?

NCT05147324 is currently completed. Last updated 23 April 2024.

Are results published for NCT05147324?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-04-23 · How we verify

NCT05147324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"MyPlan" - Individualized Planned Eating Patterns for Adolescents With Type 1 Diabetes

Completed NA Results posted Last updated 23 April 2024

What this trial tests

NA trial testing "MyPlan" - Individualized Planned Eating Pattern in Type 1 Diabetes in 52 participants. Completed in 24 April 2023.

Timeline

13 December 2021

Primary endpoint
24 April 2023

24 April 2023

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	13 December 2021
Primary completion	24 April 2023
Estimated completion	24 April 2023
Sites	2 locations across United States

Drugs / interventions tested

"MyPlan" - Individualized Planned Eating Pattern

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

University of North Carolina, Chapel Hill

Who can join

Adults 12 to 17, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percent Time in Range (Baseline) Primary · Baseline (Week 0-2)

Percentage of time spent in the glycemic range of 70-180 mg/dL between Baseline week 0-2 week of blinded continuous glucose monitor (CGM) wear time.

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	40.6	± 3.1

Percent Time in Range (Week 22-24) Primary · Week 22-24

Percentage of time spent in the glycemic range of 70-180 mg/dL during Week 22-24 of blinded continuous glucose monitor (CGM) wear time.

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	41.7	± 2.4

Adherence to Each Eating Behavior Goal Primary · Between Week 22 and Week 24

Percentage of participants who adhered to each eating behavior goal assessed through two unannounced 24-hour dietary recalls (1 weekday and 1 weekend day) collected during Week 22-24: Goal 1. 3-4 meals and 0-2 snacks; Goal 2. Spacing of meals/snacks \>2 hours and \<4 hours apart; Goal 3. Carbohydrate gram target ranges at meals (\>15% daily carbohydrate) and snacks; Goal 4. No snacking after dinner; Goal 5. Meal/snack consumed ≤2 hours of waking;

Goal 1 Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	92.5

Goal 2 Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	30.0

Goal 3 Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	87.5

Goal 4 Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	75.0

Goal 5 Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	92.5

Goal 1 Weekend

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	81.6

Goal 2 Weekend

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	36.8

Goal 3 Weekend

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	86.8

Adherence to 0-5 Eating Behavior Goals Primary · Between Week 22 and Week 24

Percentage of participants who adhered to 0-5 eating behavior goals assessed through two unannounced 24-hour dietary recalls (1 weekday and 1 weekend day) collected during Week 22 - 24. Goal 1. 3-4 meals and 0-2 snacks; Goal 2. Spacing of meals/snacks \>2 hours and \<4 hours apart Goal 3. Carbohydrate gram target ranges at meals (\>15% daily carbohydrate) and snacks Goal 4. No snacking after dinner Goal 5. Meal/snack consumed ≤2 hours of waking

Adherent to 0 Goals Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	0.0

Adherent to 1 Goal Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	0.0

Adherent to 2 Goals Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	7.5

Adherent to 3 Goals Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	25.0

Adherent to 4 Goals Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	50.0

Adherent to 5 Goals Weekday

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	17.5

Adherent to 0 Goals Weekend

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	0.0

Adherent to 1 Goal Weekend

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	0.0

Mean Adherence to Overall Eating Behavior Pattern Primary · Between Week 22 and Week 24

Mean number of eating behavior goals (range: 0-5) adhered to by participants as assessed through two unannounced 24-hour dietary recalls (1 weekday and 1 weekend day) collected during Week 22 - 24: Goal 1. 3-4 meals and 0-2 snacks; Goal 2. Spacing of meals/snacks \>2 hours and \<4 hours apart; Goal 3. Carbohydrate gram target ranges at meals (\>15% daily carbohydrate) and snacks; Goal 4. No snacking after dinner; Goal 5. Meal/snack consumed ≤2 hours of waking;

Number of Goals - Weekday

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	3.8	± 0.83

Number of Goals - Weekend

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	4.0	± 0.80

Mean Acceptability Score (Youth) Primary · Week 26

Mean composite acceptability score (range: 5-20) calculated from Likert responses (1- Strongly Agree, 2- Agree, 3- Disagree, 4- Strongly Disagree) to 5 items from an instrument that captures ease of eating pattern adoption, satisfaction, food enjoyment, sustainability, and ease of blood sugar management as perceived by youth. Lower composite acceptability scores indicate greater acceptability (5 - highly acceptable 20 - highly unacceptable).

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	7.8	± 2.4

Acceptability Percentage (Youth) Primary · Week 26

Percentage of youth with a mean acceptability score (range: 5-20) \<=10. Lower acceptability scores indicate greater acceptability (5 - highly acceptable 20 - highly unacceptable) where a score \>10 indicates the eating pattern is unacceptable. Scores calculated from Likert responses (1- Strongly Agree 2- Agree 3- Disagree 4- Strongly Disagree) to 5 scored items from an instrument that captures ease of eating pattern adoption, satisfaction, food enjoyment, sustainability, and ease of blood sugar management as perceived by youth.

Group	Value	95% CI
"MyPlan" - Individualized Planned Eating Pattern	86.4

Mean Acceptability Score (Guardian) Primary · Week 26

Mean composite acceptability score (range: 5-20) calculated from Likert responses (1- Strongly Agree, 2- Agree, 3- Disagree, 4- Strongly Disagree) to 5 items from an instrument that captures ease of eating pattern adoption, satisfaction, food enjoyment, sustainability, and ease of blood sugar management as perceived by youth's guardian. Lower composite acceptability scores indicate greater acceptability (5 - highly acceptable 20 - highly unacceptable).

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	7.8	± 2.3

Acceptability Percentage (Guardian) Primary · Week 26

Percentage of guardians with a mean acceptability score (range: 5-20) \<=10. Lower acceptability scores indicate greater acceptability (5 - highly acceptable 20 - highly unacceptable) where a score \>10 indicates the eating pattern is unacceptable. Scores calculated from Likert responses (1- Strongly Agree 2- Agree 3- Disagree 4- Strongly Disagree) to 5 scored items from an instrument that captures ease of eating pattern adoption, satisfaction, food enjoyment, sustainability, and ease of blood sugar management as perceived by youth's guardian.

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	93.2

Change in Hemoglobin A1c Percentage Secondary · Baseline (Week 0) and Endline (Week 26)

Change in point-of-care hemoglobin A1c (HbA1c) percentage.

Group	Value	95% CI
"MyPlan" - Individualized Eating Pattern	-0.32	± 0.89

Sponsor's own description

The purpose of this study is to test the acceptability and effectiveness of an individualized eating strategy as part of diabetes self-management to improve glycemic levels among youth with type 1 diabetes (T1D) and suboptimal glycemic management. Investigators will assess participant acceptability of and adherence to a 6-month individualized eating strategy ("MyPlan") characterized by approximate day-to-day consistency in the frequency and timing of meals and snacks and distribution of carbohydrate throughout the day. Within-individual change in glycemic levels between baseline and 6-months of the study will also be compared. The goal of the study is to inform the design of a future randomized clinical trial to test the addition of the MyPlan eating strategy to ongoing diabetes clinical care among youth with T1D.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Applications and prospects of biomaterials in diabetes management.
Guan W, Zhang L. · · 2025 · PMID 40124248 · DOI 10.3389/fbioe.2025.1547343

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05147324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05147324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing